Jane Street Group, LLC Argenx Se Put Options Transaction History

Jane Street Group, LLC

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$434.22 - $551.9 $15.6 Million - $19.8 Million	35,900 New	35,900 $19.5 Million
Q2 2022 Aug 16, 2022	SELL	$269.58 - $378.88 $3.4 Million - $4.77 Million	-12,600 Closed	0 $0
Q1 2022 May 17, 2022	BUY	$254.45 - $351.06 $2.19 Million - $3.02 Million	8,600 Added 215.0%	12,600 $3.97 Million
Q4 2021 Feb 15, 2022	SELL	$272.01 - $353.03 $1.17 Million - $1.52 Million	-4,300 Reduced 51.81%	4,000 $1.4 Million
Q3 2021 Nov 16, 2021	SELL	$295.0 - $350.58 $354,000 - $420,696	-1,200 Reduced 12.63%	8,300 $2.51 Million
Q2 2021 Aug 16, 2021	BUY	$257.11 - $319.92 $848,463 - $1.06 Million	3,300 Added 53.23%	9,500 $2.86 Million
Q1 2021 May 18, 2021	SELL	$268.3 - $380.31 $1.88 Million - $2.66 Million	-7,000 Reduced 53.03%	6,200 $1.71 Million
Q4 2020 Feb 17, 2021	SELL	$248.13 - $308.36 $11.4 Million - $14.2 Million	-46,100 Reduced 77.74%	13,200 $3.88 Million
Q3 2020 Nov 17, 2020	BUY	$215.51 - $272.51 $1.7 Million - $2.15 Million	7,900 Added 15.37%	59,300 $15.6 Million
Q2 2020 Aug 17, 2020	BUY	$127.44 - $232.72 $6.55 Million - $12 Million	51,400 New	51,400 $11.6 Million

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.5B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.